AnaCardio press release 2025.01.092025.01.09 / AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure Reports positive results from phase 1b study of AC01 in patients with heart failure and reduce ...
Navigating the journey of orphan drug development 2024.06.282024.06.28 / A new drug rarely takes a direct path from idea to patient, especially a first-in-class therapy. For NephroDI Therapeutics, developing a novel approach addressing the critical unmet medical need of a ...
Sound Bioventures: Putting Scandinavian Biotechs on the Global Stage 2024.06.042024.09.09 / In this keynote presentation from the BioStock Global Forum, Sound Bioventures' Managing Partner Johan Kordel discusses the importance of Scandinavian biotch companies taking a strong international p ...
Evolving to the next phase of viral therapy development 2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics 2024.04.172024.05.13 / Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolyt ...
VC Investing in Clinical Stage Biotherapeutics Companies in Europe and the U.S. 2024.02.022024.02.02 / In this episode of Engaging Alternatives Spotlight, Elana Margulies-Snyderman, Director, Publications, EisnerAmper, speaks with Bibhash Mukhopadhyay, Managing Partner, Sound Bioventures, a ventur ...
Sound Bioventures 2023 year in review 2024.01.302024.01.31 / A busy year with the final close of Sound Bioventures Fund I 2023 was a busy year for Sound Bioventures with the final close of Sound Bioventures Fund I taking the final total capital commitments ...
The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health 2023.11.032024.05.13 / Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Bre ...
Bringing everything together for an autoimmunity game changer 2023.09.202024.05.13 / At AbolerIS Pharma, it's all about creating balance. The Belgian/French biotech company is gearing up for clinical trials of a novel therapy for stabilizing chaotic immune systems. As CEO Ann Meulema ...
Reaching the next level of creating novel therapies for genetic diseases 2023.05.312024.05.13 / ARTHEx Biotech is entering a new phase in its development of breakthrough treatments for genetically-driven disorders. It’s set to begin the first clinical trials for one of its microRNA modulators a ...
The drive to adapt a lab discovery into treatment of neurodegeneration 2023.03.292024.05.13 / Teitur Trophics is breaking new ground when it comes to neurodegenerative diseases. After identifying a previously unknown means of preserving functioning brain cells, the biotech company’s founders ...
From toxin to remedy, and operating room to the boardroom 2023.03.212024.09.11 / Even though it’s based on venom from one of the deadliest snakes in the world, the lead product of biotech startup VarmX can be life-saving for patients on blood thinners. It's an unexpected turn, bu ...
